Navigation Links
FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
Date:2/29/2008

WOODCLIFF LAKE, N.J., Feb. 29 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has accepted an ACIPHEX supplemental New Drug Application (sNDA) for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in patients ages 12-16. Further, FDA has indicated that the sNDA will receive priority review in accordance with the Best Pharmaceuticals for Children Act, which provides for a 180-day review period.

ACIPHEX was discovered and developed by Eisai and is copromoted in the United States with PriCara(R), a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

About ACIPHEX(R) (rabeprazole sodium)

ACIPHEX(R) is a prescription medication. One ACIPHEX 20 mg tablet daily is used in adults for the treatment of persistent, frequent (2 or more days a week) heartburn and other symptoms associated with acid reflux disease.

ACIPHEX is also used in adults for the short-term (4 to 8 weeks) treatment in the healing and symptom relief of damaging (erosive) acid reflux disease (gastroesophageal reflux disease).

Important Safety Information

ACIPHEX has a well-established safety profile. The most common side effect possibly related to ACIPHEX is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin(R)) may need to be monitored more closely by their doctor. To learn more, talk to your doctor and see the full product information at http://www.aciphex.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
For more information about Eisai, please visit http://www.eisai.com.

ACIPHEX is a registered trademark of Eisai Co., Ltd.

Coumadin is a registered trademark of Bristol-Myers Squibb Pharma Company.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
2. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
3. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
4. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
5. Chinese SFDA Grants Immtech Fast Track Status
6. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
7. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
8. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
11. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... “The Road To Restoration”: an informative and enlightening ... hour a week showing of hands. “The Road To Restoration” is the creation of ... familiar with the brass ring that you could reach out for, and grab, on ...
(Date:12/7/2016)... ... 07, 2016 , ... “Fred Rides a Train” allows readers to tag along ... “Fred Rides a Train” is the creation of published author, Janet Morrison, who has ... in Michigan. The "Fred, the Dog" series is her first attempt at writing for ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to reduce ... drinking more water or limiting their exposure to the sun, according to a November ... group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ourselves ...
Breaking Medicine News(10 mins):